<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 11, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708238</url>
  </required_header>
  <id_info>
    <org_study_id>04032016</org_study_id>
    <nct_id>NCT02708238</nct_id>
  </id_info>
  <brief_title>Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics</brief_title>
  <official_title>Efficacy of a Standardized Extract of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) Compared With Lactobacillus Reuteri (DSM 17938) and With Simethicone for the Treatment of Infantile Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter prospective, randomized comparative study will be conducted in infants with
      colic, according to Rome III criteria. Enrolled infants will be assigned at random to receive
      Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122), L reuteri DSM
      17938 (108 CFU) or simethicone. Treatment will be given to subjects for 28 days and they will
      be followed for 4 weeks. Treatment success will be assessed at the end of study period. Daily
      crying and fussing times will be recorded in a structured diary, and maternal questionnaires
      will be completed to monitor changes in infant colic symptoms and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, multicentre, open label, randomized, controlled trial. All
      consecutive infants diagnosed with IC, according to Rome III criteria, will be prospectively
      enrolled in a 12 months period by 3 different Pediatric Gastroenterology units: Department of
      Translational Medical Science, Section of Pediatrics, University of Naples &quot;Federico II&quot;;
      Institute of Pediatrics of the University of Foggia; Endoscopy and Gastroenterology Unit,
      Department of Pediatrics, University of Messina.

      After the enrollment, all children will be randomly assigned to receive Chamomilla L.,
      Melissa Officinalis L. and tyndallized L. Acidophilus (H122) (Group A), L reuteri DSM 17938
      (108 CFU) (Group B) or Simethicone (Group C). Treatment will be given to subjects for 28
      days. The study's primary outcome is defined as a reduction in the duration of average crying
      times, from baseline (day 0) to end of treatment (day 28). The secondary outcome measure is
      the number of participants who respond to treatment on days 28. Infants who experience a
      decrease in the daily average crying time of 50% from baseline will be considered as
      responders to the treatment. Parents will be instructed to complete a structured 28-day
      maternal diary, modified from Barr et al. in order to record the frequency of colic episodes
      and the daily crying and fussing time (in minutes), feeding schedule, stool frequency and
      characteristics, and any adverse events experienced (14). Follow-up visits will be conducted
      on study days 7, 14, 21 and 28 by the same study investigator. At that visit, diaries and
      unused study products will be returned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Daily Crying Time at the End of the Treatment</measure>
    <time_frame>28 days of treatment</time_frame>
    <description>Median daily crying at the end of treatment (day 28).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>28 days of treatment</time_frame>
    <description>Number of responders defined as the number of patients who experienced a decrease in the daily average crying time of 50% from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Infantile Colics</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938 (108 CFU)</intervention_name>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone</intervention_name>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of IC according to Rome III criteria (2);

          2. age ≥2 weeks to 4 months;

          3. breast-fed or fomula-fed infants;

          4. term delivery (≥37 weeks gestation at birth);

          5. 5-minute Apgar score ≥7; and 6) birth weight ≥2500 g

        Exclusion Criteria:

          1. a major medical problem or acute illness;

          2. family history of atopy;

          3. history of antibiotic treatment before or during the study;

          4. history of probiotic supplementation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Staiano, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <results_first_submitted>April 15, 2016</results_first_submitted>
  <results_first_submitted_qc>June 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2016</results_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Erasmo Miele</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Infantile colics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="14" upper_limit="86"/>
                    <measurement group_id="B2" value="35" lower_limit="14" upper_limit="85"/>
                    <measurement group_id="B3" value="30" lower_limit="14" upper_limit="62"/>
                    <measurement group_id="B4" value="35" lower_limit="14" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Daily Crying Time at the End of the Treatment</title>
        <description>Median daily crying at the end of treatment (day 28).</description>
        <time_frame>28 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Daily Crying Time at the End of the Treatment</title>
          <description>Median daily crying at the end of treatment (day 28).</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30" upper_limit="180"/>
                    <measurement group_id="O2" value="55" lower_limit="30" upper_limit="180"/>
                    <measurement group_id="O3" value="80" lower_limit="30" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders</title>
        <description>Number of responders defined as the number of patients who experienced a decrease in the daily average crying time of 50% from baseline</description>
        <time_frame>28 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders</title>
          <description>Number of responders defined as the number of patients who experienced a decrease in the daily average crying time of 50% from baseline</description>
          <units>number of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
Lactobacillus reuteri DSM 17938 (108 CFU)</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 20 drops four times per day of a commercially available solution
Simethicone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The absence of a placebo group and the open label design represent the main limitations of this study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Annamaria Staiano</name_or_title>
      <organization>Department of Translational Medical Sciences, Section of Pediatrics, University of Naples &quot;Federico II&quot;</organization>
      <phone>00390817462679</phone>
      <email>staiano@unina.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
